The Weight-Loss Revolution People Didn’t Want (opens in new tab)

Most of the criticisms and rebuttals in this post are applicable to before 2024. By 2025, GLP-1 weight-loss drugs had become thoroughly mainstream and many skeptics have come around to the fact that these drugs are highly effective and that the side effects are manageable. But with the upcoming FDA approval of the potent triple-agonist Retatrutide, there has been renewed interest and skepticism, although less compared to pre-2024. A lot has changed since 2024. Eli Lilly’s tirzepatide portfoli...